We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+11.35%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$81.6B
AUM Growth
+$7.7B
Cap. Flow
+$798M
Cap. Flow %
0.98%
Top 10 Hldgs %
23.85%
Holding
3,095
New
53
Increased
1,513
Reduced
1,408
Closed
84

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$65.3M
2
AMZN icon
Amazon
AMZN
+$50M
3
TSLA icon
Tesla
TSLA
+$30.5M
4
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$26.6M
5
EPAM icon
EPAM Systems
EPAM
+$26.3M

Sector Composition

Rank Sector Weight
1 Technology 25.54%
2 Financials 13.15%
3 Healthcare 12.95%
4 Consumer Discretionary 12.27%
5 Industrials 8.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BHR
2501
Braemar Hotels & Resorts
BHR
$142M
$510K ﹤0.01%
99,972
+671
+0.7% +$3.3K
TRNS icon
2502
Transcat
TRNS
$871M
$510K ﹤0.01%
5,521
+134
+2% +$11.3K
ABNB icon
2503
Airbnb
ABNB
$107B
$507K ﹤0.01%
3,045
+332
+12% +$58.5K
BWB icon
2504
Bridgewater Bancshares
BWB
$603M
$507K ﹤0.01%
28,662
-610
-2% -$10.9K
SMBK icon
2505
SmartFinancial
SMBK
$888M
$506K ﹤0.01%
18,496
-30
-0.2% -$795
VUZI icon
2506
Vuzix
VUZI
$224M
$505K ﹤0.01%
58,204
-1,386
-2% -$15K
MRSN
2507
DELISTED
Mersana Therapeutics
MRSN
$502K ﹤0.01%
3,231
-79
-2% -$15.4K
UPLD icon
2508
Upland Software
UPLD
$15.4M
$502K ﹤0.01%
2,799
-51
-2% -$13K
VKTX icon
2509
Viking Therapeutics
VKTX
$4B
$501K ﹤0.01%
108,882
-646
-0.6% -$3.62K
DSGN icon
2510
Design Therapeutics
DSGN
$876M
$499K ﹤0.01%
23,289
+12,700
+120% +$218K
UTMD icon
2511
Utah Medical Products
UTMD
$225M
$499K ﹤0.01%
4,994
-52
-1% -$5.31K
WTI icon
2512
W&T Offshore
WTI
$518M
$497K ﹤0.01%
153,952
+4,339
+3% +$16.7K
STXB
2513
DELISTED
Spirit of Texas Bancshares, Inc. Common Stock
STXB
$496K ﹤0.01%
17,230
-28
-0.2% -$741
FRST icon
2514
Primis Financial Corp
FRST
$404M
$495K ﹤0.01%
32,923
-54
-0.2% -$820
OPRT icon
2515
Oportun Financial
OPRT
$372M
$492K ﹤0.01%
24,303
-329
-1% -$7.69K
CARE icon
2516
Carter Bankshares
CARE
$731M
$491K ﹤0.01%
31,925
-50
-0.2% -$753
KRO icon
2517
KRONOS Worldwide
KRO
$989M
$490K ﹤0.01%
32,673
-1,049
-3% -$14.6K
CSTR
2518
DELISTED
CapStar Financial Holdings, Inc
CSTR
$490K ﹤0.01%
23,293
-371
-2% -$7.97K
IESC icon
2519
IES Holdings
IESC
$15.2B
$489K ﹤0.01%
9,660
-157
-2% -$7.86K
RIGL icon
2520
Rigel Pharmaceuticals
RIGL
$750M
$483K ﹤0.01%
18,224
-352
-2% -$10.6K
GTHX
2521
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$481K ﹤0.01%
47,125
+65
+0.1% +$828
CVLG icon
2522
Covenant Logistics
CVLG
$872M
$480K ﹤0.01%
36,338
-70
-0.2% -$962
VAPO
2523
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$480K ﹤0.01%
2,895
-62
-2% -$10.7K
TIPT icon
2524
Tiptree Inc
TIPT
$675M
$479K ﹤0.01%
34,658
+47
+0.1% +$658
CCB icon
2525
Coastal Financial
CCB
$693M
$478K ﹤0.01%
9,446
-171
-2% -$7.08K

Similar funds

RhumbLine Advisers's Q4 2021 Portfolio in Review

As of Q4 2021, RhumbLine Advisers held 3,095 positions worth $81.6B, up 10% from $73.9B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Trading was light in Q4 2021: portfolio turnover was 4.4%. RhumbLine Advisers opened 53 new positions and exited 84, leaving the 3,095-position portfolio largely intact.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.

  • RhumbLine Advisers's largest Q4 2021 buy was Rivian: 125,331 shares worth $13M.
  • RhumbLine Advisers added most to Microsoft in Q4 2021, an estimated $65.3M increase.
  • RhumbLine Advisers's biggest Q4 2021 reduction was Berkshire Hathaway Class B, cutting an estimated $21.9M.
  • RhumbLine Advisers fully exited Kansas City Southern in Q4 2021, selling an estimated $39.1M.
  • RhumbLine Advisers's ten largest holdings make up 24% of its $81.6B portfolio in Q4 2021.
  • RhumbLine Advisers opened 53 new positions and closed 84 in Q4 2021.
  • RhumbLine Advisers's portfolio value rose 10% quarter-over-quarter to $81.6B.

Based on RhumbLine Advisers's 13F filing for Q4 2021, filed 10 Feb 2022.